Nurix Therapeutics, Inc. - Common stock (NRIX) earnings
NRIX earnings moved a median of -0.14% by the close. Quarterly and annual NRIX reports and results, each read against the price at its own news timestamp. Back to the NRIX overview →
18 measured NRIX earnings events.
Where these NRIX earnings landedvs 18 measured NRIX earnings reactions
| Middle 50% of NRIX earnings reactions | -6.87% to +3.65% |
|---|---|
| Median reaction (to close) | -0.14% |
| Measured reactions | 18 |
Point-in-time · zero look-ahead
Half of the 18 NRIX earnings events with a measured close landed between -6.87% and +3.65%; 44% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Nurix Therapeutics, Inc. For: Aug 31 | SEC filing · Form 10-Q | +0.68% | -0.14% | |
| Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update | Press release | +0.68% | -0.14% | |
| Form 10-Q Nurix Therapeutics, Inc. For: May 31 | SEC filing · Form 10-Q | -4.26% | -7.24% | |
| Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | -4.26% | -7.24% | |
| Form 10-Q Nurix Therapeutics, Inc. For: Feb 28 | SEC filing · Form 10-Q | +1.18% | -5.85% | |
| Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Press release | +1.18% | -5.85% | |
| Form 10-K Nurix Therapeutics, Inc. For: Nov 30 | SEC filing · Form 10-K | +1.64% | -3.62% | |
| Form 10-Q Nurix Therapeutics, Inc. For: Aug 31 | SEC filing · Form 10-Q | +7.05% | +0.52% | |
| Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update | Press release | +7.05% | +0.52% | |
| Form 10-Q Nurix Therapeutics, Inc. For: May 31 | SEC filing · Form 10-Q | -9.60% | -12.50% | |
| Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | Press release | -9.60% | -12.50% | |
| Form 10-Q Nurix Therapeutics, Inc. For: Feb 28 | SEC filing · Form 10-Q | +0.49% | +4.69% | |
| Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update | Press release | +0.49% | +4.69% | |
| Form 10-K Nurix Therapeutics, Inc. For: Nov 30 | SEC filing · Form 10-K | +2.25% | +0.46% | |
| Form 10-Q Nurix Therapeutics, Inc. For: Aug 31 | SEC filing · Form 10-Q | +1.83% | +7.02% | |
| Form 10-Q Nurix Therapeutics, Inc. For: May 31 | SEC filing · Form 10-Q | +0.50% | +9.02% | |
| Form 10-Q Nurix Therapeutics, Inc. For: Feb 29 | SEC filing · Form 10-Q | -0.30% | -7.21% | |
| Form 10-K Nurix Therapeutics, Inc. For: Nov 30 | SEC filing · Form 10-K | +3.78% | +6.70% |
Keep exploring
More NRIX: analyst actions → · SEC filings → · NRIX overview →